EP1157110A4 - Neutrokine-alpha et variant d'epissage de neutrokine-alpha - Google Patents
Neutrokine-alpha et variant d'epissage de neutrokine-alphaInfo
- Publication number
- EP1157110A4 EP1157110A4 EP00908739A EP00908739A EP1157110A4 EP 1157110 A4 EP1157110 A4 EP 1157110A4 EP 00908739 A EP00908739 A EP 00908739A EP 00908739 A EP00908739 A EP 00908739A EP 1157110 A4 EP1157110 A4 EP 1157110A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- neutrokine
- alpha
- splice variant
- variant
- alpha splice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07012741A EP1860190A3 (fr) | 1999-02-23 | 2000-02-22 | Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha |
Applications Claiming Priority (35)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US255794 | 1988-10-11 | ||
US09/255,794 US6716576B1 (en) | 1996-10-25 | 1999-02-23 | Method of assaying Neutrokine-α mRNA level |
US12238899P | 1999-03-02 | 1999-03-02 | |
US122388P | 1999-03-02 | ||
US12409799P | 1999-03-12 | 1999-03-12 | |
US124097P | 1999-03-12 | ||
US12659999P | 1999-03-26 | 1999-03-26 | |
US126599P | 1999-03-26 | ||
US12759899P | 1999-04-02 | 1999-04-02 | |
US127598P | 1999-04-02 | ||
US13041299P | 1999-04-16 | 1999-04-16 | |
US130412P | 1999-04-16 | ||
US13069699P | 1999-04-23 | 1999-04-23 | |
US130696P | 1999-04-23 | ||
US13127899P | 1999-04-27 | 1999-04-27 | |
US131278P | 1999-04-27 | ||
US13167399P | 1999-04-29 | 1999-04-29 | |
US131673P | 1999-04-29 | ||
US13678499P | 1999-05-28 | 1999-05-28 | |
US136784P | 1999-05-28 | ||
US14265999P | 1999-07-06 | 1999-07-06 | |
US142659P | 1999-07-06 | ||
US14582499P | 1999-07-27 | 1999-07-27 | |
US145824P | 1999-07-27 | ||
US16723999P | 1999-11-24 | 1999-11-24 | |
US167239P | 1999-11-24 | ||
US16862499P | 1999-12-03 | 1999-12-03 | |
US168624P | 1999-12-03 | ||
US17110899P | 1999-12-16 | 1999-12-16 | |
US171108P | 1999-12-16 | ||
US17162699P | 1999-12-23 | 1999-12-23 | |
US17601500P | 2000-01-14 | 2000-01-14 | |
US176015P | 2000-01-14 | ||
PCT/US2000/004336 WO2000050597A2 (fr) | 1999-02-23 | 2000-02-22 | Neutrokine-alpha et variant d'epissage de neutrokine-alpha |
US171626P | 2009-04-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07012741A Division EP1860190A3 (fr) | 1999-02-23 | 2000-02-22 | Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1157110A1 EP1157110A1 (fr) | 2001-11-28 |
EP1157110A4 true EP1157110A4 (fr) | 2006-05-10 |
Family
ID=27586018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07012741A Withdrawn EP1860190A3 (fr) | 1999-02-23 | 2000-02-22 | Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha |
EP00908739A Withdrawn EP1157110A4 (fr) | 1999-02-23 | 2000-02-22 | Neutrokine-alpha et variant d'epissage de neutrokine-alpha |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07012741A Withdrawn EP1860190A3 (fr) | 1999-02-23 | 2000-02-22 | Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP1860190A3 (fr) |
JP (2) | JP2003526330A (fr) |
AU (2) | AU777536B2 (fr) |
CA (1) | CA2363112A1 (fr) |
NZ (2) | NZ513290A (fr) |
WO (1) | WO2000050597A2 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217788B2 (en) | 1996-03-14 | 2007-05-15 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta polypeptides |
US6541224B2 (en) | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
ATE247482T1 (de) | 1999-01-25 | 2003-09-15 | Biogen Inc | Baff, dessen inhibitoren und dessen verwendung zur modulierung der b-zell-antwort |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
EP1860190A3 (fr) * | 1999-02-23 | 2008-03-12 | Human Genome Sciences, Inc. | Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha |
WO2000068378A1 (fr) | 1999-05-06 | 2000-11-16 | National Jewish Medical And Research Center | Molecules d'acide nucleique, proteines et recepteurs tall-1, et procedes d'utilisation |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
JP2003521931A (ja) | 2000-02-11 | 2003-07-22 | バイオジェン インコーポレイテッド | Tnfファミリーの異種ポリペプチド |
US6969519B2 (en) | 2000-03-10 | 2005-11-29 | Human Genome Sciences, Inc. | Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17) |
US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
ATE494304T1 (de) | 2000-06-16 | 2011-01-15 | Human Genome Sciences Inc | Immunspezifisch bindende antikörper gegen blys |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
JP2004537290A (ja) | 2001-05-24 | 2004-12-16 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 腫瘍壊死因子δ(APRIL)に対する抗体 |
MXPA03010747A (es) | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. |
AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
WO2004094620A2 (fr) | 2003-03-28 | 2004-11-04 | Biogen Idec Ma Inc. | Recepteurs baff tronques |
US20060171919A1 (en) * | 2005-02-01 | 2006-08-03 | Research Development Foundation | Targeted polypeptides |
US8808696B2 (en) | 2005-08-09 | 2014-08-19 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
EA016083B1 (ru) | 2005-08-09 | 2012-02-28 | Займоджинетикс, Инк. | СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
EP3037544A1 (fr) | 2005-10-13 | 2016-06-29 | Human Genome Sciences, Inc. | Procedes et compositions destinees au traitement de patients atteints de lupus erythematosus systémique positifs pour des auto-anticorps |
ES2618543T3 (es) | 2005-11-23 | 2017-06-21 | Genentech, Inc. | Métodos y composiciones relacionados con ensayos de linfocitos B |
US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
EP2035028A2 (fr) | 2006-05-15 | 2009-03-18 | Ares Trading S.A. | Procédés de traitement des maladies auto-immunes à l'aide d'une molécule de fusion taci-ig |
CA2667802A1 (fr) * | 2006-11-03 | 2008-05-29 | Northwestern University | Therapie de la sclerose en plaque |
US20110038885A1 (en) * | 2007-07-26 | 2011-02-17 | Zheng Xin Dong | Chemokine analogs |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018921A1 (fr) * | 1996-10-25 | 1998-05-07 | Human Genome Sciences, Inc. | Neutrokine alpha |
WO2000050597A2 (fr) * | 1999-02-23 | 2000-08-31 | Human Genome Sciences, Inc. | Neutrokine-alpha et variant d'epissage de neutrokine-alpha |
US6403770B1 (en) * | 1996-10-25 | 2002-06-11 | Human Genome Sciences, Inc. | Antibodies to neutrokine-alpha |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027114A2 (fr) * | 1996-12-17 | 1998-06-25 | Schering Corporation | Antigenes de surface mammaliens et reactifs associes |
CA2232743A1 (fr) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | Tl5, homologue tnf |
EE200000148A (et) * | 1997-09-12 | 2001-02-15 | Biogen, Incorporated | Kay - uus immuunsüsteemi valk |
AU2093499A (en) * | 1997-12-30 | 1999-07-19 | Chiron Corporation | Members of tnf and tnfr families |
-
2000
- 2000-02-22 EP EP07012741A patent/EP1860190A3/fr not_active Withdrawn
- 2000-02-22 EP EP00908739A patent/EP1157110A4/fr not_active Withdrawn
- 2000-02-22 JP JP2000601161A patent/JP2003526330A/ja active Pending
- 2000-02-22 AU AU30028/00A patent/AU777536B2/en not_active Expired
- 2000-02-22 CA CA002363112A patent/CA2363112A1/fr not_active Abandoned
- 2000-02-22 WO PCT/US2000/004336 patent/WO2000050597A2/fr not_active Application Discontinuation
- 2000-02-22 NZ NZ513290A patent/NZ513290A/en not_active IP Right Cessation
-
2003
- 2003-11-14 NZ NZ529555A patent/NZ529555A/en not_active IP Right Cessation
-
2005
- 2005-01-20 AU AU2005200237A patent/AU2005200237B2/en not_active Expired
-
2007
- 2007-04-19 JP JP2007111070A patent/JP2007277249A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018921A1 (fr) * | 1996-10-25 | 1998-05-07 | Human Genome Sciences, Inc. | Neutrokine alpha |
US6403770B1 (en) * | 1996-10-25 | 2002-06-11 | Human Genome Sciences, Inc. | Antibodies to neutrokine-alpha |
WO2000050597A2 (fr) * | 1999-02-23 | 2000-08-31 | Human Genome Sciences, Inc. | Neutrokine-alpha et variant d'epissage de neutrokine-alpha |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch Week 200053, Derwent World Patents Index; Class B04, AN 2000-572093, XP002331367 * |
Also Published As
Publication number | Publication date |
---|---|
JP2007277249A (ja) | 2007-10-25 |
EP1157110A1 (fr) | 2001-11-28 |
EP1860190A2 (fr) | 2007-11-28 |
AU2005200237B2 (en) | 2007-11-29 |
EP1860190A3 (fr) | 2008-03-12 |
CA2363112A1 (fr) | 2000-08-31 |
AU3002800A (en) | 2000-09-14 |
AU777536B2 (en) | 2004-10-21 |
WO2000050597A2 (fr) | 2000-08-31 |
NZ513290A (en) | 2004-05-28 |
AU2005200237A1 (en) | 2005-02-17 |
JP2003526330A (ja) | 2003-09-09 |
NZ529555A (en) | 2005-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1157110A4 (fr) | Neutrokine-alpha et variant d'epissage de neutrokine-alpha | |
HRP20060251B1 (hr) | Supstituirani oksazolidinoni i njihova uporaba | |
EP1309718A4 (fr) | Neutrokine-alpha et variant d'epissage de neutrokine-alpha | |
AU3620600A (en) | Skin-marking devices and their use | |
GB9712347D0 (en) | Vaccine | |
GB9711990D0 (en) | Vaccine | |
EP1507793A4 (fr) | Neutrokine-alpha et variant d'epissage de neutrokine-alpha | |
GB2350631B (en) | Combination whipstock and anchor | |
HUP0203896A3 (en) | Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof | |
GB2352523B (en) | Fluid-gauging systems and methods | |
GB0023323D0 (en) | Arylhydantoin derivatives and uses thereof | |
EP1194147A4 (fr) | Derives d'arylthiazolidinedione et d'aryloxazolidinedione | |
GB9704349D0 (en) | Levobupivacaine and its use | |
TW424891U (en) | Holding and fixing structure | |
NO991348D0 (no) | Oljebr°nnr°r | |
EP1229913A4 (fr) | 1-benzazepines substituees et leurs derives | |
IL129907A0 (en) | Alternative splice variants | |
GB0021915D0 (en) | Creating and managing E-receipts | |
AU2669201A (en) | Taccalonolides and their use | |
GB9704370D0 (en) | Levobupivacaine and its use | |
HK1046707A1 (zh) | 中性活動(NEUTROKINE)-α與中性活動-α粘接變異 | |
GB9929581D0 (en) | Comjpositions and their use | |
GB2354395B (en) | Telephone system and circuitry | |
GB2389158B (en) | Anchorage | |
GB9722023D0 (en) | Levobupivacaine and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010924 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060328 |
|
17Q | First examination report despatched |
Effective date: 20061219 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070630 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1046707 Country of ref document: HK |